Cullinan Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) is a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class, disease-modifying therapies. Originally centered on oncology, the company expanded its strategic focus in early 2024 to encompass autoimmune diseases, leveraging its core expertise in T cell engagers. Its lead clinical assets include CLN-978, a highly potent subcutaneous CD19xCD3 bispecific T cell engager being evaluated for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA); velinotamig, a BCMAxCD3 bispecific T cell engager for autoimmune diseases; and zipalertinib, an oral EGFR exon 20 insertion inhibitor for non-small cell lung cancer (NSCLC) developed in partnership with Taiho Pharmaceutical.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting and expanding the clinical pipeline from oncology into immunology, specifically leveraging T-cell engager (TCE) expertise to target B-cell mediated autoimmune conditions.
Expected impact: Establishes Cullinan as a leading player in the high-growth autoimmune T-cell engager space, diversifying beyond oncology.
Advancing lead oncology asset zipalertinib through regulatory submission and clinical trials in partnership with Taiho Oncology.
Expected impact: Brings Cullinan's first asset to potential commercialization, unlocking up to $130 million in regulatory milestones and a 50/50 U.S. profit share.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured global rights (excluding Greater China) to velinotamig, a clinical-stage BCMAxCD3 bispecific T-cell engager, to complement Cullinan's existing CD19 candidate (CLN-978) and address a broader range of autoimmune diseases.
Terms: $20 million upfront license fee, with Genrix eligible to receive up to $292 million in development and regulatory milestones, up to $400 million in sales-based milestones, and tiered royalties from mid-single digits to mid-teens.
Collaborating on the development and commercialization of zipalertinib for EGFR exon 20 insertion non-small cell lung cancer (NSCLC).
Terms: Cullinan is eligible for up to $130 million in U.S. regulatory milestones and a 50/50 profit share on potential U.S. sales.